Sitagliptin

Generic Name: Sitagliptin

Brand Names: Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₅F_₆N_₅O

CAS Number: 486460-32-6

Unique Ingredient Identifier: QFP0P1DV7Z

Background: Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on Oct...

Indication: Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.

It is also used in combination with metformin or ertugliflozin.

Associated Conditions: Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes

Phase 4

Conditions: Diabetes Mellitus, Type 2
Severe Insulin Deficient Diabetes

Interventions: Drug: Glimepiride
Drug: Sitagliptin

First Posted Date: 2022-05-23

Last Posted Date: 2022-05-23

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 192

Registration Number: NCT05386186

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Please Select, China

The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Phase 2

Conditions: Immune Thrombocytopenia
Blood Coagulation Disorders
Thrombocytopenia
Physiological Effects of Drugs

Interventions: Drug: Danazol
Drug: Sitagliptin

First Posted Date: 2022-04-29

Last Posted Date: 2022-04-29

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 120

Registration Number: NCT05353673

Locations: 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China

Cognitive Protective Effect of Newer Antidiabetic Drugs

Conditions: Type 2 Diabetes

Interventions: Drug: Dapagliflozin
Drug: Empagliflozin
Drug: Canagliflozin
Drug: Sitagliptin
Drug: Saxagliptin
Drug: Linagliptin
Drug: Vildagliptin

First Posted Date: 2022-04-26

Last Posted Date: 2022-07-26

Lead Sponsor: Alexandria University

Target Recruit Count: 100

Registration Number: NCT05347459

Locations: 🇪🇬
Alexandria University, Alexandria, Egypt

Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components

Phase 1

Completed

Conditions: Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)

Interventions: Drug: Dapagliflozin/sitagliptin FDC
Drug: Sitagliptin
Drug: Dapagliflozin

First Posted Date: 2022-03-04

Last Posted Date: 2022-07-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 46

Registration Number: NCT05266404

Locations: 🇩🇪
Research Site, Berlin, Germany

Effects of Sitagliptin in Relatives of T1D Patients

Phase 2

Not yet recruiting

Conditions: Type 1 Diabetes

Interventions: Device: Professional CGM
Drug: Sitagliptin

First Posted Date: 2022-02-02

Last Posted Date: 2023-05-10

Lead Sponsor: University of Milan

Target Recruit Count: 70

Registration Number: NCT05219409

Locations: 🇮🇹
ASST FBF Sacco, Milan, Italy

Replication of the GRADE Diabetes Trial in Healthcare Claims Data

Completed

Conditions: Diabetes

Interventions: Drug: Glimepiride
Drug: Sitagliptin

First Posted Date: 2021-10-29

Last Posted Date: 2023-07-27

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 6403

Registration Number: NCT05099198

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Sitagliptin
Drug: Dapagliflozin

First Posted Date: 2021-05-12

Last Posted Date: 2023-07-28

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 87727

Registration Number: NCT04882813

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study

Phase 2

Conditions: Type 1 Diabetes
Monogenic Diabetes

Interventions: Drug: Metformin Extended Release Oral Tablet
Drug: Sitagliptin

First Posted Date: 2020-06-01

Last Posted Date: 2024-03-08

Lead Sponsor: Joslin Diabetes Center

Target Recruit Count: 21

Registration Number: NCT04409795

Locations: 🇺🇸
Joslin Diabetes Center, Boston, Massachusetts, United States

The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients

Phase 3

Conditions: Covid19
Diabetes Mellitus, Type 2
CKD

Interventions: Drug: Sitagliptin

First Posted Date: 2020-04-28

Last Posted Date: 2021-09-28

Lead Sponsor: University of Milan

Target Recruit Count: 170

Registration Number: NCT04365517

Locations: 🇮🇹
ASST FBF Sacco, Milan, Italy

Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Cognitive Functions Confusion

Interventions: Drug: Canagliflozin
Drug: Sitagliptin

First Posted Date: 2020-03-11

Last Posted Date: 2024-05-30

Lead Sponsor: Third Military Medical University

Target Recruit Count: 100

Registration Number: NCT04304261

Locations: 🇨🇳
Zhiming Zhu, Chongqing, Chongqing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy